

# 外泌体在肺癌中的研究进展

《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R] 期数: 2019年09期 页码: 1651-1654 栏目: 综述 出版日期: 2019-03-30

**Title:** Research progress of exosomes in lung cancer

**作者:** 罗洋冲<sup>1</sup>; 刘晶晶<sup>2</sup>; 朱家宏<sup>1</sup>; 安乐<sup>1</sup>; 浦潇<sup>1</sup>; 王周清<sup>1</sup>  
1.曲靖市第二人民医院心胸外科; 2.药剂科, 云南 曲靖 655000

**Author(s):** Luo Xiangchong<sup>1</sup>; Liu Jingjing<sup>2</sup>; Zhu Jiahong<sup>1</sup>; An Le<sup>1</sup>; Pu Xiao<sup>1</sup>; Wang Zhouqing<sup>1</sup>  
1.Department of Cardiothoracic Surgery; 2.Department of Pharmacy,Qujing Second People's Hospital,Yunnan Qujing 655000,China.

**关键词:** 外泌体; 肺癌; 诊断; 治疗

**Keywords:** exosomes; lung cancer; diagnose; treatment

**分类号:** R734.2

**DOI:** 10.3969/j.issn.1672-4992.2019.09.044

**文献标识码:** A

**摘要:** 外泌体 (exosomes) 是由多种细胞分泌的具有脂质双分子层结构的纳米级膜囊小泡, 其内含有蛋白质、脂质、核酸等大量生物活性物质。研究表明, 外泌体在肺癌的发生发展过程中发挥着重要作用, 尤其是在肺癌的早期诊断、侵袭和转移、预后评估以及治疗等方面的作用成为目前研究的热点。因此, 关于外泌体的研究将在转化医学的研究模式下, 为肺癌临床早期诊断、治疗及预后评估带来新的契机。本文对外泌体在肺癌中的研究进展作一综述。

**Abstract:** Exosomes are Nano-sized membrane vesicle with lipid bilayer structure that are secreted by a variety of cells.It contains a large number of bioactive substances,such as protein,lipid,nucleic acid and so on.Research shows that exosomes play an important role in the process of development of lung cancer,especially in the early diagnosis of lung cancer,invasion and metastasis and prognosis assessment and treatment of lung cancer have become the focus of current research.Therefore,the study on exosomes will bring new opportunities for the early diagnosis and treatment of lung cancer and prognosis assessment in the mode of translational medicine.This article reviews the research progress of exosomes in lung cancer.

## 参考文献/REFERENCES

- [1] Chen W,Zhang R,Baade PD,et al.Cancer statistics in China,2015 [J] .CA Cancer J Clin,2016,66(2):115-132.
- [2] Siegel RL,Miller KD,Jemal A.Cancer statistics,2016 [J] .CA Cancer J Clin,2016,66(1):7-30.
- [3] Tanoue LT,Tanner T,Gould MK,et al.Lung cancer screening [J] .Am J Respir Crit Care Med,2015,191(1):19-33.
- [4] Hyenne V,Apaydin A,Rodriguez D,et al.RAL-1 controls multivesicular body biogenesis and exosome secretion [J] .J Cell Biol,2015,211(1):27-37.
- [5] Ferguson SW,Nguyen J.Exosomes as therapeutics:The implications of molecular composition and exosomal heterogeneity [J] .J Control Release,2016,228:179-190.
- [6] Johnstone RM,Bianchini A,Teng K.Reticulocyte maturation and exosome release:Transferrin receptor containing exosomes shows multiple plasma membrane functions [J] .Blood,1989,74(5):1844-1851.
- [7] Mao L,Li J,Chen WX,Exosomes decrease sensitivity of breast cancer cells to adriamycin by delivering microRNAs [J] .Tumor Biology,2016,37(4):5247.
- [8] Dong L,Lin W,Qi P,et al.Circulating long RNAs in serum extracellular vesicles:Their characterization and potential application as biomarkers for diagnosis of colorectal cancer [J] .Cancer Epidemiol Biomarkers Prev,2016,25(7):1158-1166.
- [9] Xu R,Greening DW,Zhu HJ,et al.Extracellular vesicle isolation and characterization:Toward clinical application [J] .J Clin Invest,2016,126(4):1152-1162.
- [10] Witwer KW,Buzas EI,Bemis LT,et al.Standardization of sample collection,isolation and analysis methods in extracellular vesicle research [J] .J Extracell Vesicles,2013,2:1-25.
- [11] Meehan K,Vella LJ.The contribution of tumour-derived exosomes to the hallmarks of cancer [J] .Critical Reviews in Clinical Laboratory Sciences,2016,53(2):121.
- [12] Yang C,Gu WB,Zhang WS,et al.Extraction and identification of semen-derived exosomes using peg600 [J] .Journal of Southern Medical University,2016,36(11):1531-1535.

- [13] Guo L, Guo N. Exosomes: Potent regulators of tumor malignancy and potential bio-tools in clinical application [J]. *Crit Rev Oncol Hematol*, 2015, 95(3):346-358.
- [14] Bian S, Zhang L, Duan L, et al. Extracellular vesicles derived from human bone marrow mesenchymal stem cells promote angiogenesis in a rat myocardial infarction model [J]. *J Mol Med (Berl)*, 2014, 92(4):387-397.
- [15] Wilson CM, Naves T, Vincent F, et al. Sortilin mediates the release and transfer of exosomes in concert with two tyrosine kinase receptors [J]. *J Cell Sci*, 2014, 127(Pt 18):3983-3997.
- [16] Kosaka N, Lguchi H, Hagiwara K, et al. Neutral sphingomyelinase 2 (nSMase2)-dependent exosomal transfer of angiogenic microRNAs regulate cancer cell metastasis [J]. *J Biol Chem*, 2013, 288(15):10849-10859.
- [17] Emma Bell, Molly A, Taylor. Functional roles for exosomal MicroRNAs in the tumour microenvironment [J]. *Comput Struct Biotechnol J*, 2017, 15:8-13.
- [18] Cui H, Seubert B, Stahl E, et al. Tissue inhibitor of metalloproteinases-1 induces a pro-tumorigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes [J]. *Oncogene*, 2015, 34(28):3640-3650.
- [19] Rahman MA, Barger JF, Lovat F, et al. Lung cancer exosomes as drivers of epithelial-mesenchymal transition [J]. *Oncotarget*, 2016, 7(34):54852-54866.
- [20] Ko H, Jeon H, Lee D, et al. Sanguin H6 suppresses TGF-beta induction of the epithelial-mesenchymal transition and inhibits migration and invasion in A549 lung cancer [J]. *Bioorg Med Chem Lett*, 2015, 25(23):5508-5513.
- [21] Yang J, Liu W, Lu X, et al. High expression of small GTPase Rab3D promotes cancer progression and metastasis [J]. *Oncotarget*, 2015, 6(13):11125-11138.
- [22] Li X, Wang S, Zhu R, et al. Lung tumor exosomes induce a pro-inflammatory phenotype in mesenchymal stem cells via NF- $\kappa$ B-TLR signaling pathway [J]. *J Hematol Oncol*, 2016, 9(1):42.
- [23] Wysoczynski M, Ratajczak MZ. Lung cancer secreted microvesicles: Underappreciated modulators of microenvironment in expanding tumors [J]. *Int J Cancer*, 2009, 125(7):1595-1603.
- [24] Huang SH, Li Y, Zhang J, et al. Epidermal growth factor receptor-containing exosomes induce tumor-specific regulatory T cells [J]. *Cancer Invest*, 2013, 31(5):330-335.
- [25] Fabbri M, Paone A, Calore F, et al. MicroRNAs bind to toll-like receptors to induce prometastatic inflammatory response [J]. *Proc Natl Acad Sci USA*, 2012, 109(31):E2110-E2116.
- [26] Xiao X, Yu S, Li S, et al. Exosomes: Decreased sensitivity of lung cancer A549 cells to cisplatin [J]. *PLoS One*, 2014, 9(2):e89534.
- [27] Qin X, Yu S, Xu X, et al. Comparative analysis of microRNA expression profiles between A549, A549/DDP and their respective exosomes [J]. *Oncotarget*, 2017, 8(26):42125-42153.
- [28] Li XQ, Liu JT, Fan LL, et al. Exosomes derived from gefitinib-treated EGFR-mutant lung cancer cells alter cisplatin sensitivity via up-regulating autophagy [J]. *Oncotarget*, 2016, 7(17):24585-24595.
- [29] Tang Y, Cui Y, Li Z, et al. Radiation-induced miR-208a increases the proliferation and radioresistance by targeting p21 in human lung cancer cells [J]. *J Exp Clin Cancer Res*, 2016, 35(1):1-14.
- [30] Giallombardo M, Chacartegui Borrás J, Castiglia M, et al. Exosomal miRNA analysis in non-small cell lung cancer (NSCLC) patients' plasma through qPCR: A feasible liquid biopsy tool [J]. *J Vis Exp*, 2016, 27(111):e53900.
- [31] Cazzoli R, Buttitta F, Di Nicola M, et al. microRNA derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer [J]. *J Thorac Oncol*, 2013, 8(9):1156-1162.
- [32] Rodriguez M, Silva J, Lopez-Alfonso A, et al. Different exosome cargo from plasma/bronchoalveolar lavage in non-small cell lung cancer [J]. *Genes Chromosomes Cancer*, 2014, 53(9):713-724.
- [33] Vanni I, Alama A, Grossi F, et al. Exosomes: A new horizon in lung cancer [J]. *Drug Discov Today*, 2017(17):30110-30115.
- [34] Jakobsen KR, Paulsen BS, Baek R, et al. Exosomal proteins as potential diagnostic markers in advanced non-small cell lung cancer carcinoma [J]. *J Extracell Vesicles*, 2015, 4:26659.
- [35] Li Y, Zhang Y, Qiu F, et al. Proteomic identification of exosomal LRG1: A potential urinary biomarker for detecting NSCLC [J]. *Electrophoresis*, 2011, 32(15):1976-1983.
- [36] Ueda K, Ishikawa N, Tatsuguchi A, et al. Antibody-coupled monolithic silica microtips for high-throughput molecular profiling of circulating exosomes [J]. *Sci Rep*, 2014, 4:6232.
- [37] Marleau AM, Chen CS, Joyce JA, et al. Exosome removal as a therapeutic adjuvant in cancer [J]. *J Transl Med*, 2012, 10(31):1-12.
- [38] Morse MA, Garst J, Osadat T, et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer [J]. *J Transl Med*, 2005, 3(1):9.
- [39] Brahmer JR. Harnessing the immune system for the treatment of non-small-cell lung cancer [J]. *J Clin Oncol*, 2013, 31(8):1021-1028.
- [40] Besse B, Charrier M, Lapiere V, et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC [J]. *Oncoimmunology*, 2016, 5(4):e1071008.
- [41] Aqil F, Kausar H, Agrawal AK, et al. Exosomal formulation enhances therapeutic response of celastrol against lung cancer [J]. *Exp Mol Pathol*, 2016, 101:12-21.
- [42] Agrawal AK, Aqil F, Jeyabalan J, et al. Milk-derived exosomes for oral delivery of paclitaxel [J]. *Nanomedicine*, 2017, 13(5):1627-1636.
- [43] Yang G, Zhang W, Yu C, et al. MicroRNA let-7: Regulation, single nucleotide polymorphism, and therapy in lung cancer [J]. *J Cancer Res Ther*, 2015, 11(Suppl 1):C1-C6.
- [44] Mungala R, Aqil F, Gupta RC. Exosomal miRNAs as biomarkers of recurrent lung cancer [J]. *Tumour Biol*, 2016, 37:10703-10714.
- [45] Dinh TKT, Fendler W, Chalubinska-Fendler J, et al. Circulating miR-29a and miR-150 correlate with

delivered dose during thoracic radiation therapy for non-small cell lung cancer [J]. Radiation Oncol, 2016, 11:61.

---

备注/Memo: -

---

更新日期/Last Update: 2019-03-30